NCT02033798

Brief Summary

The purpose of this study is to determine whether medical treatment for bladder outlet obstruction is effective in improvement of glomerular filtration rate and/or proteinuria.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
34

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2014

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 8, 2014

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 13, 2014

Completed
19 days until next milestone

Study Start

First participant enrolled

February 1, 2014

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2016

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2016

Completed
Last Updated

January 17, 2014

Status Verified

January 1, 2014

Enrollment Period

1.9 years

First QC Date

January 8, 2014

Last Update Submit

January 15, 2014

Conditions

Keywords

UrodynamicsGlomerular Filtration Rate

Outcome Measures

Primary Outcomes (5)

  • Maximal flow rate

    This parameter can be obtained from urodynamic study.

    6 months

  • Maximal detrusor pressure

    This parameter can be obtained from urodynamic study.

    6 months

  • Bladder outlet obstruction index

    This parameter can be obtained from urodynamic study.

    6 months

  • schäfer grade

    This parameter can be obtained from urodynamic study.

    6 months

  • Compliance

    This parameter can be obtained from urodynamic study.

    6 months

Secondary Outcomes (2)

  • Estimated glomerular filtration rate

    6 months

  • Urinary protein to creatinine ratio

    6 months

Other Outcomes (1)

  • International prostate symptom score

    6 months

Study Arms (1)

Tamsulosin

EXPERIMENTAL

The dosage form of Tamsulosin is tablet, dosage is 0.2mg, frequency is once daily and duration is 6 months.

Drug: Tamsulosin

Interventions

Once Daily 0.2mg per oral for 6 months

Also known as: Harnal D, Tamsnal
Tamsulosin

Eligibility Criteria

Age40 Years - 80 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men with low urinary tract symptoms aged between 40 and 80
  • Estimated glomerular filtration rate \< 60 or evidence of proteinuria
  • Bladder outlet obstruction index \> 40, Schäfer grade 2 or more, maximal flow rate lower than 10 cc/s or postvoid residual urine \> 100cc

You may not qualify if:

  • Bladder outlet obstruction index less than 40, Schäfer grade 0 or 1, maximal flow rate higher than 10 ml/s and postvoid residual urine less than 100cc
  • Want surgical procedure
  • Evidence of prostate cancer or bladder cancer
  • Major depressive disorder, Dementia, Parkinson's disease or neurological deficits
  • History of pelvic irradiation
  • Uncontrolled diabetes mellitus or hypertension
  • Symptomatic orthostatic hypotension

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

St. Vincent's Hospital

Suwon, Gyeonggi-do, 442-723, South Korea

Location

MeSH Terms

Conditions

Kidney Failure, ChronicProstatic Hyperplasia

Interventions

Tamsulosin

Condition Hierarchy (Ancestors)

Renal Insufficiency, ChronicRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsProstatic DiseasesGenital Diseases, MaleGenital Diseases

Intervention Hierarchy (Ancestors)

BenzenesulfonamidesSulfonamidesAmidesOrganic ChemicalsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsSulfonesSulfur Compounds

Study Officials

  • Seung-Ju Lee, MD, PhD

    The Catholic University of Korea

    STUDY CHAIR
  • Dong Sup Lee, MD, PhD

    The Catholic University of Korea

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Seung-Ju Lee, MD, PhD

CONTACT

Dong Sup Lee, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior researcher

Study Record Dates

First Submitted

January 8, 2014

First Posted

January 13, 2014

Study Start

February 1, 2014

Primary Completion

January 1, 2016

Study Completion

June 1, 2016

Last Updated

January 17, 2014

Record last verified: 2014-01

Locations